Abstract: The present invention provides (1) a polypeptide containing amino acids 1 to 269 of the amino acid sequence shown in SEQ ID No: 1, (2) polypeptide containing amino acids 1 to 290 of the amino acid sequence shown in SEQ ID No. 1, (3) a polypeptide containing amino acids −28 to 269 of the amino acid sequence shown in SEQ ID No. 1, and (4) a polypeptide containing amino acids −28 to 290 of the amino acid sequence shown in SEQ ID No. 1. The present invention also provides a fusion protein in which residues 1 to 269 of SEQ ID No. 1 are linked to a second polypeptide and a fusion protein in which residues 1 to 290 of SEQ ID No. 1 are linked to a second polypeptide.
Abstract: Compositions are administered to block IgE binding to receptors and ultimately displace native IgE from mast cells and related cell types, to prevent the activation of these cells during an allergic response. The compositions consist of a pharmaceutically acceptable carrier for systemic or local administration and an amount of compound binding specifically to the Fc&egr;RI IgE binding sites, and more preferably, Fc&egr;RI and Fc&egr;RII IgE binding sites, to prevent activation and degranulation of mast cells in response to exposure to allergens. The compounds can consist of IgE molecules and fragments and modifications thereof, such as IgE fragments, humanized or single chain IgE antibodies or fragments thereof, IgE with a modified Fab, non-crosslinkable IgE, or peptidomimetics which bind to the same site on the receptor as the IgE, jointly referred to herein as “IgE fragments” unless otherwise stated.
Abstract: A modified immunoglobulin (Ig) molecule incorporates, preferably in one or more non-CDR loops, one or more foreign antigenic peptides such as a ras peptide. The antigen binding site of the immunoglobulin preferably recognises dendritic antigen presenting cells (APCs). The modified Ig can thus be taken up by dendritic APCs and the foreign antigenic peptide presented on MHC II to naive T-helper cells which stimulate cytotoxic T-cells via the production inter alia of IL-2. Modified Igs of the invention can be used to stimulate the immune system which has apparently become tolerant of a mutant protein, e.g., in the case of certain types of cancer, or it could be used for vaccination against viral infections. The modified Ig can be expressed from recombinant host cells from which it is secreted, notwithstanding the presence of the foreign pepide in a loop of the molecule.
Type:
Grant
Filed:
September 29, 1997
Date of Patent:
September 25, 2001
Inventors:
Bjarne Bogen, Inger Sandlie, Sigbjørn Fossum, Siri Mjaaland, Elin Lunde, Ingunn B. Rasmussen
Abstract: The present invention provides a unique src-family kinase (SFK) that plays a key role in the transformation of early-stage embryonic cells to mesodermal cells. Furthermore, this src-family kinase is likely to be a proto-oncogene. The nucleic acid and amino acid sequences are disclosed.
Type:
Grant
Filed:
January 12, 1999
Date of Patent:
September 18, 2001
Assignee:
The Rockerfeller University
Inventors:
Ali Hemmait-Brivanlou, Daniel C. Weinstein
Abstract: Antibody molecules specific for surface structures of antigen presenting cells that have been modified to include an antigen moiety at a specific site therein to produce novel conjugate antibody molecules are disclosed. These conjugate molecules are produced by genetic modification of genes encoding light and heavy chains of the surface structure specific antibody, and expression in mammalian cells to produce the conjugate antibody. The conjugate antibody retained specificity for antigen presenting cells and contained the antigen moiety. The conjugate antibody molecules deliver the antigen to antigen presenting cells to produce an enhanced immune response to a host immunized therewith.
The conjugate antibody molecules and nucleic acid molecules encoding them are useful as antigens and as immunogens in diagnostic and prophylactic applications.
Type:
Grant
Filed:
October 3, 1997
Date of Patent:
September 18, 2001
Assignee:
Aventis Pasteur Limited
Inventors:
Naveen N. Anand, Brian H. Barber, George C. Cates, Judith E. Caterini, Michel H. Klein
Abstract: The present invention relates to an assay for the detection of modified nucleoside levels in a patient. Detection of the modified nucleoside levels in a patient having a disease such as cancer allows for the progression of the disease to be followed and therapeutic regimens to be altered. Such an assay is particularly useful in following the response of cancer patients to chemotherapeutic treatment.
Abstract: This invention is related to the DNA encoding the porcine complement inhibitor (pMCPcDNA), the porcine complement inhibitor expressed by the DNA, and a method for screening for the porcine complement inhibitor. pMCPcDNA can be obtained by preparing a cDNA library from porcine vascular endothelium and screening for cDNA encoding the porcine complement inhibitor. pMCPcDNA of this invention is useful for production of the porcine complement inhibitor by genetic recombination and for analysis for the promoter region of the porcine complement inhibitor.
Type:
Grant
Filed:
April 13, 1998
Date of Patent:
August 7, 2001
Assignee:
Nippon Meat Packers, Inc.
Inventors:
Koji Toyomura, Hiroshi Murakami, Tamotsu Shigehisa
Abstract: The invention provides a human prostate associated Ets protein (PRAEP) and polynucleotides which identify and encode PRAEP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PRAEP.
Type:
Grant
Filed:
April 3, 1998
Date of Patent:
July 24, 2001
Assignee:
Incyte Genomics, Inc.
Inventors:
Olga Bandman, Karl J. Guegler, Preeti Lal, Neil C. Corley
Abstract: The present invention is directed to an Assay for high capacity screening of substances interfering with the attachment of human IgE to its high affinity receptor and/or of substances capable of detaching already bound IgE from this receptor and for the differential analysis between autoimmune disorders and classical allergies.
Type:
Grant
Filed:
June 25, 1998
Date of Patent:
July 10, 2001
Assignee:
Novartis AG
Inventors:
Manfred Auer, Franz Hammerschmid, Georg Stingl
Abstract: CRFG-1b polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CRFG-1b polypeptides and polynucleotides in the design of protocols for the treatment of chronic renal disease, renal ischemia, diabetic nephropathy, acute renal failure, neurodegenerative disease, and Alzheimer's disease, among others, and diagnostic assays for such conditions.
Type:
Grant
Filed:
February 9, 1998
Date of Patent:
July 3, 2001
Assignee:
SmithKline Beecham Corporation
Inventors:
Nicholas J Laping, Barbara Olson, Yuan Zhu
Abstract: The present invention fulfills a need in the art for methods that promote hematopoietic and mesenchymal stem and lineage-specific cell proliferation and differentiation by growth in the presence of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments and analogues thereof and AII AT2 type 2 receptor agonists.
Abstract: Method for the isolation and characterization of a 140,000 dalton cell surface glycoprotein with the properties expected of a fibronectin receptor is described.
Type:
Grant
Filed:
May 20, 1998
Date of Patent:
June 5, 2001
Assignee:
La Jolla Cancer Research Foundation
Inventors:
Eric I. Ruoslahti, Michael D. Pierschbacher
Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.
Abstract: The present invention provides substantially pure proapoptotic dependence peptides. The peptides consist substantially of the sequence of an active dependence domain selected from the group of dependence polypeptides consisting of p75NTR, androgen receptor, DCC, huntingtin polypeptide, Machado-Joseph disease gene product, SCA1, SCA2, SCA6 and atrophin-1 polypeptide. Substantially pure proapoptotic dependence peptides include SATLDALLAALRRI (SEQ ID NO:3), Q14 (SEQ ID NO:7), SATLDALLAALGGI (SEQ ID NO:4), SATLDALLAALRGI (SEQ ID NO:5), SATLQALLAALRRI (SEQ ID NO:6), tat-GG-SATLDALLAALRRI (SEQ ID NO:37) and tat-GG-Q14 (SEQ ID NO:36).
Abstract: PIGR-1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PIGR-1 polypeptides and polynucleotides in the design of protocols for the treatment of rheumatoid arthritis (RA), multiple sclerosis (MS), psoriasis, systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD), among others and diagnostic assays for such conditions.
Type:
Grant
Filed:
April 28, 1999
Date of Patent:
May 15, 2001
Assignee:
SmithKline Beecham Corporation
Inventors:
Shujian Wu, Raymond W Sweet, Alemseged Truneh, Mark Robert Hurle
Abstract: The present invention provides compositions and methods for gene identification, as well as drug discovery and assessment. In particular, the present invention provides components of an E3 complex involved in ubiquitination of cell cycle regulators and other proteins, as well as members of a class of proteins that directly function in recognition of ubiquitination targets. The present invention also provides sequences of multiple F-box proteins.
Type:
Grant
Filed:
October 15, 1998
Date of Patent:
May 15, 2001
Assignee:
Baylor College of Medicine
Inventors:
Jeffrey Wade Harper, Stephen J. Elledge, Jeffrey T. Winston
Abstract: Methods for treating and modulating an inflammatory response using compositions containing a primarily monomeric or primarily dimeric form of galectin-1. The dimeric form stimulates apoptosis of activated neutrophils while the monomeric form inhibits apoptosis of activated neutrophils. Methods of screening for compounds which have galectin-1-like functions are also identified.
Type:
Grant
Filed:
July 1, 1999
Date of Patent:
May 1, 2001
Assignee:
The Board of Regents of the University of Oklahoma
Abstract: The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function, as indicated by studies using temperature sensitive mutants of ICP4 that transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene, such as an &agr;4 gene, methods of inhibiting ICP4's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections. Further, the present invention discloses that the HSV-1 mutant lacking the &agr;4 gene, has a secondary mutation in the gene Us3 specifying a protein kinase.
Abstract: This invention relates to modulation of programmed cell death. It also relates to transgenic non-human animals comprising a disrupted Ich-3 gene and methods of making these animals. The Ich-3 mutant animals exhibit resistance to septic shock and defects in follficulogenesis. This invention also relates to methods of using the transgenic animals to screen for compounds to treat septic shock and defective folliculogenesis. Moreover, this invention also relates to methods of treating septic shock in normal individuals by inhibiting ICH-3.